Welcome to DolPHIN2

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

The project will investigate whether dolutegravir is superior to efavirenz-based regimens (the current standard of care within sub-Saharan Africa) at preventing mother to child transmission of HIV for women who begin HIV treatment in the third trimester of pregnancy. We aim to establish high-quality evidence and operational guidance for the use of dolutegravir (DTG) in late pregnancy through:

- A multi-site clinical trial – taking place in Uganda and South Africa

- Qualitative studies – assessing the acceptability of dolutegravir and the reasons for late presentation in pregnancy

- A Pharmacoeconomic study – assessing the cost effectiveness of dolutegravir against the standard of care in South Africa and Uganda.

Read more about DolPHIN 2 , find out about our team and access the latest resources on PMTCT and the project.

DolPHIN 2 is funded by UNITAID.